- Peer divergence26.6 robust σ
- Persistence0 periods
- Independent evidence1 group
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAbCellera Biologics Inc.'s latest supported as-filed period reports revenue of $4.1M, 76.3% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
Unusual transitions and combinations worth inspecting—not forecasts or recommendations.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 52.64% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 640.07% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -76.29% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 187.11% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -1550.05% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 1135.48% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +29.9% from the comparable as-filed period. The change ranks at the 64th percentile of 47 prior comparable changes.
Net income changed -59.6% from the comparable as-filed period. The change ranks at the 52th percentile of 62 prior comparable changes.
Operating income changed -26.6% from the comparable as-filed period. The change ranks at the 29th percentile of 38 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ABCL · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-058684SEC ↗4Aug 18, 2026Period Aug 18, 20260001834423-26-000008SEC ↗4Aug 14, 2026Period Aug 14, 20260001834411-26-000008SEC ↗4Aug 14, 2026Period Aug 12, 20260001628280-26-057007SEC ↗8-KAug 13, 2026Period Aug 12, 20260001193125-26-349353SEC ↗4Aug 13, 2026Period Aug 11, 20260001628280-26-056653SEC ↗8-KAug 10, 2026Period Aug 10, 20260001703057-26-000053SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 24, 2026Filed Aug 24, 2026 | Hayden Michael RDirector | Open Market PurchaseIndirect | 53,613 | $11 | $570,442 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 18, 2026 | Montalbano John S.Director | Open Market PurchaseDirect | 10,000 | $11 | $110,300 | Form 4 ↗ |
| Aug 14, 2026Filed Aug 14, 2026 | Booth AndrewChief Financial Officer | Open Market PurchaseDirect | 37,200 | $10 | $383,904 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 14, 2026 | Hayden Michael RDirector | Open Market PurchaseIndirect | 46,387 | $10 | $481,033 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 303.36% · OPTIONAL
Operating margin changed -125981 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 38 prior comparable changes.
Research & development changed +17.3% from the comparable as-filed period. The change ranks at the 29th percentile of 38 prior comparable changes.
Revenue changed -76.3% from the comparable as-filed period. The change ranks at the 55th percentile of 38 prior comparable changes.
Stock-based compensation changed -13.5% from the comparable as-filed period. The change ranks at the 21th percentile of 38 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001703057-26-000049| Aug 11, 2026Filed Aug 13, 2026 |
| Hayden Michael RDirector |
| GiftIndirect |
| 50,000 |
| $0 |
| $0 |
| Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Seely LynnDirector | Grant Or AwardDirect | 152,207 | $0 | $0 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Sandor VictorDirector | Grant Or AwardDirect | 152,207 | $0 | $0 | Form 4 ↗ |
| Jun 11, 2026Filed Jun 12, 2026 | Hayden Michael RDirector | Grant Or AwardDirect | 111,701 | $0 | $0 | Form 4 ↗ |
| Jun 11, 2026Filed Jun 12, 2026 | Quake StephenDirector | Grant Or AwardDirect | 111,701 | $0 | $0 | Form 4 ↗ |
| Jun 11, 2026Filed Jun 12, 2026 | Montalbano John S.Director | Grant Or AwardDirect | 111,701 | $0 | $0 | Form 4 ↗ |
| Jun 3, 2026Filed Jun 3, 2026 | Booth AndrewChief Financial Officer | Option ExerciseDirect | 250,000 | $0 | $47,500 | Form 4 ↗ |
| Jun 3, 2026Filed Jun 3, 2026 | Booth AndrewChief Financial Officer | Option ExerciseDirect | 250,000 | $0 | $0 | Form 4 ↗ |
| May 14, 2026Filed May 18, 2026 | Montalbano John S.Director | Open Market PurchaseDirect | 20,000 | $5 | $95,400 | Form 4 ↗ |